FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2888778231> ?p ?o ?g. }

• W2888778231 endingPage "S41" @default.
• W2888778231 startingPage "S30" @default.
• W2888778231 abstract "Type 2 diabetes (T2DM) is associated with significant impairment in health-related quality of life (HRQoL). A patient-centered collaborative approach is recommended to optimize clinical outcomes, including HRQoL, in this patient population. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide effective glycemic control and have demonstrated beneficial effects on HRQoL and treatment satisfaction. Available once-weekly GLP-1 RAs may offer enhanced convenience compared with daily GLP-1 RAs and include exenatide extended-release (ER), dulaglutide, and semaglutide. This article reviews the impact of once-weekly GLP-1 RAs on HRQoL and treatment satisfaction in patients with T2DM. Compared with oral antihyperglycemic drugs, insulin, and daily GLP-1 RAs, once-weekly GLP-1 RAs offer benefits with regard to HRQoL and treatment satisfaction. These benefits appear to be largely mediated by relative drug effects on glycemic control, weight, and hypoglycemia. While there was not an overall class benefit of once-weekly GLP-1 RAs compared with daily GLP-1 RAs on HRQoL and treatment satisfaction, results suggested that once-weekly GLP-1 RAs may enhance certain elements of treatment satisfaction and increase willingness to continue treatment. In 2 studies comparing once-weekly GLP-1 RAs with each other, semaglutide produced significantly greater improvement in overall treatment satisfaction compared with exenatide ER but not dulaglutide. Once-weekly GLP-1 RAs represent an effective and convenient treatment option that may potentially increase treatment satisfaction and enhance adherence, contributing to improved health outcomes.This supplement was funded by Novo Nordisk. Billings reports personal fees from Dexcom, Novo Nordisk, and Sanofi. Handelsman reports research grants from Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Grifols, Janssen, Lexicon, Merck, Novo Nordisk, Regeneron, and Sanofi; speaker fees from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim-Lilly, Janssen, Merck, Novo Nordisk, Regeneron, and Sanofi; and has served in advisory capacity to Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eisai, Intarcia, Janssen, Lilly, Merck, Merck-Pfizer, Novo Nordisk, Regeneron, and Sanofi. Heile reports speaker fees from and has served as advisor to Novo Nordisk. Schneider reports advisory board fees from Intarcia, Lilly, and Novo Nordisk. Wyne has nothing to disclose." @default.
• W2888778231 created "2018-09-07" @default.
• W2888778231 creator A5016242440 @default.
• W2888778231 creator A5024720272 @default.
• W2888778231 creator A5037652425 @default.
• W2888778231 creator A5051239455 @default.
• W2888778231 creator A5087749895 @default.
• W2888778231 date "2018-09-01" @default.
• W2888778231 modified "2023-10-14" @default.
• W2888778231 title "Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus" @default.
• W2888778231 cites W1906693641 @default.
• W2888778231 cites W1975970108 @default.
• W2888778231 cites W1979568434 @default.
• W2888778231 cites W1991682850 @default.
• W2888778231 cites W2005469189 @default.
• W2888778231 cites W2027186239 @default.
• W2888778231 cites W2030042684 @default.
• W2888778231 cites W2030546890 @default.
• W2888778231 cites W2037396061 @default.
• W2888778231 cites W2046048169 @default.
• W2888778231 cites W2053144796 @default.
• W2888778231 cites W2054981500 @default.
• W2888778231 cites W2055754603 @default.
• W2888778231 cites W2065319712 @default.
• W2888778231 cites W2071782474 @default.
• W2888778231 cites W2090054860 @default.
• W2888778231 cites W2098322453 @default.
• W2888778231 cites W2104252114 @default.
• W2888778231 cites W2107949845 @default.
• W2888778231 cites W2107967018 @default.
• W2888778231 cites W2128825255 @default.
• W2888778231 cites W2129934471 @default.
• W2888778231 cites W2132322340 @default.
• W2888778231 cites W2138035442 @default.
• W2888778231 cites W2138077952 @default.
• W2888778231 cites W2140367917 @default.
• W2888778231 cites W2143474617 @default.
• W2888778231 cites W2158350833 @default.
• W2888778231 cites W2163502113 @default.
• W2888778231 cites W2165556241 @default.
• W2888778231 cites W2166886145 @default.
• W2888778231 cites W2199333711 @default.
• W2888778231 cites W2207970920 @default.
• W2888778231 cites W234533797 @default.
• W2888778231 cites W2462710388 @default.
• W2888778231 cites W2473786944 @default.
• W2888778231 cites W2570241083 @default.
• W2888778231 cites W2578084918 @default.
• W2888778231 cites W2585146202 @default.
• W2888778231 cites W2586129535 @default.
• W2888778231 cites W2590405401 @default.
• W2888778231 cites W2602700371 @default.
• W2888778231 cites W2604469807 @default.
• W2888778231 cites W2607173673 @default.
• W2888778231 cites W2695892839 @default.
• W2888778231 cites W2787255324 @default.
• W2888778231 cites W3168475087 @default.
• W2888778231 cites W4241476243 @default.
• W2888778231 cites W48883754 @default.
• W2888778231 cites W906438903 @default.
• W2888778231 doi "https://doi.org/10.18553/jmcp.2018.24.9-a.s30" @default.
• W2888778231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30156447" @default.
• W2888778231 hasPublicationYear "2018" @default.
• W2888778231 type Work @default.
• W2888778231 sameAs 2888778231 @default.
• W2888778231 citedByCount "9" @default.
• W2888778231 countsByYear W28887782312019 @default.
• W2888778231 countsByYear W28887782312020 @default.
• W2888778231 countsByYear W28887782312021 @default.
• W2888778231 countsByYear W28887782312022 @default.
• W2888778231 countsByYear W28887782312023 @default.
• W2888778231 crossrefType "journal-article" @default.
• W2888778231 hasAuthorship W2888778231A5016242440 @default.
• W2888778231 hasAuthorship W2888778231A5024720272 @default.
• W2888778231 hasAuthorship W2888778231A5037652425 @default.
• W2888778231 hasAuthorship W2888778231A5051239455 @default.
• W2888778231 hasAuthorship W2888778231A5087749895 @default.
• W2888778231 hasBestOaLocation W28887782311 @default.
• W2888778231 hasConcept C126322002 @default.
• W2888778231 hasConcept C134018914 @default.
• W2888778231 hasConcept C159110408 @default.
• W2888778231 hasConcept C170493617 @default.
• W2888778231 hasConcept C185280430 @default.
• W2888778231 hasConcept C2775944032 @default.
• W2888778231 hasConcept C2777180221 @default.
• W2888778231 hasConcept C2778938600 @default.
• W2888778231 hasConcept C2779306644 @default.
• W2888778231 hasConcept C2779829264 @default.
• W2888778231 hasConcept C2779951463 @default.
• W2888778231 hasConcept C2780473172 @default.
• W2888778231 hasConcept C2780533449 @default.
• W2888778231 hasConcept C2780668416 @default.
• W2888778231 hasConcept C2781308992 @default.
• W2888778231 hasConcept C2908647359 @default.
• W2888778231 hasConcept C2909862629 @default.
• W2888778231 hasConcept C555293320 @default.
• W2888778231 hasConcept C71924100 @default.
• W2888778231 hasConcept C99454951 @default.

• next